[go: up one dir, main page]

AR061643A1 - Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1. - Google Patents

Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1.

Info

Publication number
AR061643A1
AR061643A1 ARP070102822A ARP070102822A AR061643A1 AR 061643 A1 AR061643 A1 AR 061643A1 AR P070102822 A ARP070102822 A AR P070102822A AR P070102822 A ARP070102822 A AR P070102822A AR 061643 A1 AR061643 A1 AR 061643A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
atom
coor5
alkoxy
Prior art date
Application number
ARP070102822A
Other languages
English (en)
Inventor
Patrick Mougenot
Claudie Namane
Eric Nicolai
Francois Pacquet
Christophe Philippo
Olivier Venier
Olivier Crespin
Cecile Pascal
Michel Aletru
Alain Braun
Stefan Gussregen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0605786A external-priority patent/FR2902790A1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR061643A1 publication Critical patent/AR061643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Métodos para su preparacion, una composicion farmacéutica que los comprende y el empleo de éstos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11b-HSD1. Reivindicacion 1: Compuestos que responden a la formula (1): en la que: X representa un átomo de carbono, de oxigeno, de azufre o de nitrogeno o el grupo O=S=O; R1a,b,c,d y R2a,b,c,d idénticos o diferentes, representan cada uno un átomo de hidrogeno o de halogeno, alquilo C1-5, alcoxi C1-5, halogenoalquilo C1-5, hidroxi, hidroxi-alquilo C1-5, ciano, -COOR5, -NR6R7, -COOR5-alquilo C1-5, NR6R7-alquilo C1-5, -CONR6R7, CONR6R7-alquilo C1-5, -SO2NR6R7, -COR5, arilo o heteroarilo, arilo-alquilo C1-5, heteroarilo-alquilo C1-5, heterocicloalquil-alquilo C1-5, todos los grupos arilo, heteroarilo que pueden estar opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados entre grupos ciano, COOR5, CONR6R7, SO2R5, alcoxi C1-5, OCH2CONR6R7, un átomo de halogeno, halogenoalquilo C1-5 y solo un grupo arilo-alquilo C1-5 puede opcionalmente estar sustituido con un grupo heteroarilo; o (R2a) o (R2b) pueden asimismo formar con el átomo de carbono al que están unidos un grupo C=O, C=CF2; o (R2a) y/o (R2b) pueden asimismo formar con el o los átomos a los que están unidos un grupo cicloalquilo C3-6, pudiendo ser estos ciclos espiro cuando son transportados por el mismo átomo de carbono y ser opcionalmente sustituidos con uno a tres átomos de halogenos; o (R1d) y (R2a) pueden formar igualmente con los átomos a los que están unidos un grupo cicloalquilo C3-7; los grupos R3a,b representan cada uno, un átomo de hidrogeno, fluor o un grupo alquilo C1-5, alcoxi C1-5, alcoxi-alquilo C1-5, hidroxi, hidroxi- alquilo C1-5, halogenoalquilo C1-5, ciano, -COOR5, -NR6R7, -COOR5-alquilo C1-5, NR6R7-alquilo C1-5, -CONR6R7, CONR6R7-alquilo C1-5; R4 representa: un grupo alquilo C1-5; un grupo cicloalquilo C3-6; un grupo heterocicloalquilo; un grupo arilo mono- o bi-cíclico que tiene de 5 a 10 átomos de carbono; un grupo heteroarilo mono- o bicíclico que tiene de 2 a 9 átomos de carbono; cuando R4 es un grupo arilo o heteroarilo o heterocicloalquilo, puede ser opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre los átomos de halogeno, los grupos alquilo C1-5, alcoxi C1-5, halogenoalquilo C1-5, hidroxi, hidroxi-alquilo C1-5, alcoxi C1-5-alquilo C1-5, ciano, fenilo opcionalmente sustituido, bencilo opcionalmente sustituido, -COOR5, - NR6R7, -COOR5-alquilo C1-5, -NR6R7-alquilo C1-5, -CONR6R7, SO2NR6R7; o R3a,b y R4 son, transportados por átomos de carbono diferentes o transportados por un mismo átomo de carbono y, cuando son transportados por el mismo átomo de carbono, pueden formar juntos un ciclo en posicion espiro, en particular un ciclo de formula (2), (3), (4) o (5) en las que: el enlace de puntos es un enlace simple o un enlace doble; s es un numero entero igual a 0, 1, 2 o 3; t es un numero entero igual a 0, 1, 2 o 3, no pudiendo ser s y t iguales a la vez a 0; R8 representa un átomo de hidrogeno o de halogeno, alquilo C1-5, alcoxi C1-5, trifluorometilo, hidroxi, hidroximetilo, ciano, -COOR5, -NR6R7; R9 representa un átomo de hidrogeno o alquilo C1-5, hidroxi; Y representa un enlace o un átomo de carbono o de nitrogeno; n es un numero entero igual a 0 o 1; o, p, q y r, idénticos o diferentes, son numeros enteros iguales a 0, 1 o 2; i y j son numeros enteros iguales a 0, 1, 2, 3 o 4; R5 representa un átomo de hidrogeno, alquilo C1-5, cicloalquilo C3-6, halogenoalquilo C1-5; R6 y R7, idénticos o diferentes, representan cada uno un átomo hidrogeno, alquilo C1-5, cicloalquilo C3-6, alquilcarbonilo C1-5, hidroximetilalquilo C1-5, alcoximetilo C1- 5, alquilo C1-5, arilo, heterocicloalquilo opcionalmente sustituido, -SO2R5 o pueden formar junto con el átomo de nitrogeno al que están unidos un heterocicloalquilo opcionalmente sustituido, entendiéndose que cuando X = CH2, n = 0, R1a,b,c,d = H, R2a,b,c,d = H, R3a,b = H entonces el grupo R4 debe ser diferente de fenilo opcionalmente sustituido con un átomo de halogeno o un grupo alquilo C1-5, trifluorometilo, alcoxi C1-5; en estado de base o de sal de adicion de ácido, así como en estado de hidrato o de solvato.
ARP070102822A 2006-06-27 2007-06-26 Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1. AR061643A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605786A FR2902790A1 (fr) 2006-06-27 2006-06-27 Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique
FR0611239 2006-12-22

Publications (1)

Publication Number Publication Date
AR061643A1 true AR061643A1 (es) 2008-09-10

Family

ID=38692075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102822A AR061643A1 (es) 2006-06-27 2007-06-26 Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1.

Country Status (16)

Country Link
US (1) US7947834B2 (es)
EP (1) EP2044057A2 (es)
JP (1) JP2009541463A (es)
KR (1) KR20090021192A (es)
AR (1) AR061643A1 (es)
AU (1) AU2007264791A1 (es)
BR (1) BRPI0713042A2 (es)
CA (1) CA2652852A1 (es)
CL (1) CL2007001886A1 (es)
IL (1) IL195820A0 (es)
MX (1) MX2008016563A (es)
PE (1) PE20080212A1 (es)
RU (1) RU2009102527A (es)
TW (1) TW200811158A (es)
UY (1) UY30448A1 (es)
WO (1) WO2008000950A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2450081T3 (es) 2006-06-27 2014-03-21 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados como moduladores del receptor GPR40
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
FR2948369B1 (fr) 2009-07-27 2013-04-12 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR2948370B1 (fr) * 2009-07-27 2013-04-05 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX370535B (es) 2013-11-18 2019-12-17 Forma Therapeutics Inc Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
FI4334289T3 (fi) * 2021-05-07 2025-08-27 Organon R&D Finland Oy Uusia heterosyklisiä yhdisteitä, koostumuksia, menetelmiä niiden valmistamiseksi ja niiden käyttöjä
EP4538270A4 (en) * 2022-06-10 2025-07-02 Sapiensbio Inc NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE INGREDIENT

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130795B1 (en) 1983-07-05 1988-11-23 Pfizer Inc. Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
US6369057B1 (en) * 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
AU657986B2 (en) * 1991-06-14 1995-03-30 Pharmacia & Upjohn Company Imidazo(1,5-a)quinoxalines
WO2001087834A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
ITMI20012060A1 (it) * 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JP2006506451A (ja) * 2002-10-11 2006-02-23 アストラゼネカ アクチボラグ １，４−ジ置換ピペリジン誘導体および１１−βＨＳＤ１阻害薬としてのそれらの使用
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
US20060116382A1 (en) * 2004-11-10 2006-06-01 Wenqing Yao Lactam compounds and their use as pharmaceuticals
KR20070097441A (ko) * 2004-11-18 2007-10-04 인사이트 산 디에고 인코포레이티드 11-β 하이드록실 스테로이드 데하이드로게나제 유형 1의억제제 및 이를 사용하는 방법
JP5140577B2 (ja) * 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
AU2006255944B2 (en) * 2005-06-08 2010-03-04 Japan Tobacco Inc. Heterocyclic compound

Also Published As

Publication number Publication date
TW200811158A (en) 2008-03-01
CA2652852A1 (fr) 2008-01-03
BRPI0713042A2 (pt) 2013-01-08
US20090176775A1 (en) 2009-07-09
EP2044057A2 (fr) 2009-04-08
WO2008000950A3 (fr) 2008-02-14
AU2007264791A1 (en) 2008-01-03
WO2008000950A2 (fr) 2008-01-03
US7947834B2 (en) 2011-05-24
JP2009541463A (ja) 2009-11-26
IL195820A0 (en) 2009-09-01
KR20090021192A (ko) 2009-02-27
CL2007001886A1 (es) 2009-11-10
RU2009102527A (ru) 2010-08-10
MX2008016563A (es) 2009-03-02
UY30448A1 (es) 2008-01-31
PE20080212A1 (es) 2008-04-25

Similar Documents

Publication Publication Date Title
AR061643A1 (es) Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1.
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
CO2018002060A2 (es) Compuestos farmacéuticos
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
MX2018010805A (es) Agentes antivirales contra la hepatitis b.
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
AR046964A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion.
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
CY1116439T1 (el) Τριαζολοπυριδινες
AR080982A1 (es) Derivados de quinoxalina
CR20120302A (es) Derivados bencimidazol-imidazol
UY33961A (es) Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona
AR097435A1 (es) 6-alquinilpiridinas
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CO6771450A2 (es) Ureas asimétricas y usos médicos de las mismas
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
MX376743B (es) Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
ECSP13013075A (es) Método de tratamiento de la fiebre dengue

Legal Events

Date Code Title Description
FA Abandonment or withdrawal